The investigation, published in Annals of Internal Medicine, used real-world health data from a large cohort of U.S. adults aged 18 to 65 diagnosed with type 2 diabetes. The researchers focused on people who started GLP-1 therapy, including commonly used agents such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), and analyzed outcomes consistent with ischemic optic neuropathy.

Ischemic optic neuropathy occurs when the optic nerve’s blood supply is impaired, leading to abrupt changes in vision. Clinically, this often presents as blurring, dimming, or loss of part of the visual field in one eye rather than total blindness, and it can be permanent—particularly for the non-arteritic anterior form, which accounts for most reported cases.

Although the absolute event rate is low, the study estimated that the risk increase corresponded to roughly three to four additional cases per 10,000 patients treated with GLP-1s over 18 months. “Rare” does not mean “irrelevant,” the authors note, because sudden vision loss can be irreversible and may require urgent specialist assessment.

The researchers emphasize that the findings describe an association rather than proof of causation. Differences in baseline health among patients initiating GLP-1 treatment could partly explain the signal. Even so, the growing use of GLP-1 therapies in both diabetic and non-diabetic populations heightens the importance of vigilant medication safety monitoring.

Lead author Chintan Dave, a pharmacy and pharmacoepidemiology researcher at Rutgers, added that patients who develop symptoms should not wait. Early recognition of visual changes and prompt ophthalmologic evaluation may be especially crucial for those with higher baseline risk.

The study also suggests demographic patterns: many reported cases occurred among men or among men and women aged 50 to 65. That detail could help clinicians identify who may benefit from heightened counseling or faster response when visual symptoms appear.

Future work is needed to determine whether GLP-1 exposure directly contributes to ischemic optic neuropathy or whether unmeasured factors are driving the observed association. For now, the overall risk remains low, but the authors argue that patients and clinicians should be aware of the potential.

Subject of Research: People
Article Title: Glucagon-Like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy: A Target Trial Emulation
News Publication Date: 14-Jul-2026
Web References: https://www.acpjournals.org/doi/10.7326/ANNALS-25-00860
References: 10.7326/ANNALS-25-00860
Image Credits:

Keywords: GLP-1, ischemic optic neuropathy, type 2 diabetes, obesity, sudden vision loss, semaglutide, tirzepatide

NAION is a disorder characterized by sudden, painless vision loss due to compromised blood flow to the anterior portion of the optic nerve. Traditionally, it has been associated with vascular risk factors such as hypertension, diabetes, and nocturnal hypotension. The study’s findings lend important clinical insights, highlighting that initiation of semaglutide in this patient population correlates with approximately double the risk of developing NAION compared to patients starting therapy with SGLT2 inhibitors.

This study is especially significant given the widespread use of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), which has revolutionized the management of type 2 diabetes through its robust glycemic control and cardiovascular benefits. Nonetheless, these findings emphasize the imperative for vigilant risk assessment and patient counseling about the potential ocular risks associated with this medication.

The research was conducted using a large dataset drawn from Veterans Affairs medical centers across the United States, incorporating extensive longitudinal medical records. Employing robust cohort study methodology, investigators controlled for confounding variables pivotal in diabetic populations, such as age, glycemic control, existing vascular comorbidities, and medication adherence patterns. This methodological rigor strengthens the validity of the observed association between semaglutide use and NAION risk.

Despite the statistical doubling in relative risk, it is critical to underscore that the absolute incidence of NAION remained low. This paradox highlights a common challenge in interpreting pharmacoepidemiologic data—while relative risk metrics indicate a substantial increase, the real-world event rate remains infrequent. Hence, clinical decisions should balance this nuanced risk against the comprehensive benefits offered by semaglutide.

The pathophysiological mechanisms potentially underlying this association remain speculative at this stage. Hypotheses include microvascular ischemic events promoted by GLP-1 receptor agonists or perhaps changes in intraocular pressure dynamics. Further research is warranted to elucidate these biological pathways, which may also contribute to broader understandings of diabetic ocular complications.

From a clinical practice perspective, these results underscore the need for eye screening protocols and heightened surveillance shortly after initiating semaglutide, especially in patients with pre-existing ocular or microvascular risk factors. Multidisciplinary collaboration between endocrinologists, ophthalmologists, and primary care providers becomes pivotal to optimize patient outcomes while minimizing adverse events.

In addition, the study’s findings have regulatory and pharmaco-safety implications. Given the increasing prevalence of diabetes and expanding indications for semaglutide, including weight management, awareness of such adverse effects must inform labeling, clinical guidelines, and post-marketing surveillance. This will ensure that healthcare professionals are equipped to mitigate risks through informed prescribing and patient education.

Patient counseling emerges as a crucial component in the therapeutic decision-making process. Patients must be adequately informed about the rare but real potential for vision-threatening complications associated with semaglutide. Emphasis on prompt reporting of visual symptoms can facilitate early diagnosis and management, potentially preserving vision.

While the study contributes valuable epidemiological evidence, it also highlights the broader challenge in diabetes pharmacotherapy—balancing potent metabolic control with vigilance for uncommon, yet severe adverse effects. As newer agents enter the market, ongoing real-world outcome studies are essential to continually refine therapeutic strategies and optimize patient safety.

In conclusion, this extensive investigation delineates a doubled relative risk of NAION following semaglutide initiation in U.S. veterans with type 2 diabetes compared to initiation of SGLT2 inhibitors, albeit with a low absolute event rate. These insights are vital for tailoring individualized treatment plans that maximize benefits while attentively managing risks, thereby advancing diabetes care in the 21st century.

Subject of Research: Risk assessment of nonarteritic anterior ischemic optic neuropathy (NAION) in type 2 diabetes patients initiating semaglutide compared to sodium-glucose cotransporter-2 inhibitors.

Article Title: [Not provided]

News Publication Date: [Not provided]

Web References: [Not provided]

References: (doi:10.1001/jamaophthalmol.2025.6262)

Keywords: Neuropathic pain, Ischemia, Optics, Type 2 diabetes, United States population, Medications, Glucose, Risk factors, Medical treatments, Cohort studies, Ophthalmology